There are concerns that sotrovimab has reduced efficacy at reducing hospitalisation risk against the BA.2 sub-lineage of the Omicron SARS-CoV-2 variant. We performed a retrospective cohort (n = 8850) study of individuals treated with sotrovimab in the community, with the objective of assessing whether there were any differences in risk of hospitalisation of BA.2 cases compared with BA.1. We estimated that the hazard ratio of hospital admission with a length of stay of 2 days or more was 1.17 for BA.2 compared with BA.1 (95%CI 0.74-1.86). These results suggest that the risk of hospital admission was similar between the two sub-lineages.
Keywords: COVID-19 therapeutics; SARS-CoV-2; neutralising monoclonal antibodies; severity.
© 2023 Crown copyright. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd. This article is published with the permission of the Controller of HMSO and the King’s Printer for Scotland.